Overview
IXHL market data
Price History
IXHL price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$40.83 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.84 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -18,137.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.49 – $27.69 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $38.6M · P/B 0.47 · P/S 394.34.
Company News
Incannex Healthcare Receives Final A$5.1M R&D Tax Incentive Refund Following Approval Of Its Overseas Findings And Amendment Of Its FY25 Tax ReturnBenzinga · Aug 11, 2026, 12:10 PM
8-K filing — Incannex Healthcare Inc. (IXHL)SEC EDGAR · Aug 11, 2026, 11:30 AM
Incannex Healthcare Begins Participant Screening In Its DReAMzz Phase 2 Dose Confirmation Study Evaluating IHL-42X To Treat Obstructive Sleep ApneaBenzinga · Jul 23, 2026, 12:04 PM
Incannex Healthcare Secures U.S. Patent For Compositions And Methods Of Treatment For Obstructive Sleep ApneaBenzinga · Jun 25, 2026, 12:10 PM
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial FlexibilityGlobenewswire Inc · Jun 10, 2026, 12:15 PM
Incannex Healthcare Q3 EPS $(0.35) Beats $(0.79) EstimateBenzinga · May 15, 2026, 11:07 PM